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Introduction: Respiratory tract symptoms (RTS), common in athletes during heavy training and 
after events, result in impaired readiness for events and race times.  Since the 1980’s exercise 
immunologists have investigated the aetiological factors surrounding the development of 
exercise induced RTS in order to develop effective preventative strategies.  A number of theories 
have been put forward and explored, such as increased susceptibility to infection, ‘run-away’ 
inflammatory response and reactivation of prior viral infection.  It has been suggested that the 
mechanisms producing exercise induced inflammation could potentiate allergic responses in 
sensitized individuals and recently allergic response has been proposed as a potential contributor 
to exercise induced RTS.  Certainly allergic reactions can produce a range of respiratory 
symptoms; however the relationship between allergic sensitization, allergic reaction and the 
incidence of post-exercise RTS has not been well defined. 
 
Objectives: The primary objective of this study was to document the incidence of RTS for two 
weeks before and two weeks after a three-day trail run and relate these to the general systemic 
and salivary immunological profile as well as atopic status of the participants.  The secondary 
objective was to validate the use of the Phadiatop® assay as a predictor of allergy-associated 
post-race RTS in trail runners. 
 
Study Design and Methods:  The study formed part of a larger, descriptive field study 
examining the physiological responses of trail runners during the Three Cranes Challenge, a 
multi-day 95 km event divided into three stages, in Karkloof, KwaZulu-Natal.  Outcome 
measures examined included self- reported RTS over a 31 day period (pre, during and post race), 
as well as pre-race Phadiatop® status, salivary IgA (sIgA) concentrations  and changes in 
concentrations of serum IgE (sIgE), cortisol, high sensitivity C-Reactive Protein (hs-CRP) and 
differential leukocyte counts.  The haematological and salivary parameters were obtained at 8 
time points before, during and after the event.  
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A convenience sample of 22 individuals was used and two separate analyses were conducted on 
the data. The inclusion criteria of the first analysis were met by 14 participants.  In this analysis, 
the incidence of RTS was related to each participant’s general immunological profile.  Sixteen of 
the subjects met the inclusion criteria for the second analysis, in which their Phadiatop® status 
was related to their sIgE and blood eosinophil and basophil concentrations in order to establish 
the validity of the Phadiatop® assay in predicting the development of allergy–associated post-
exercise RTS in trail runners.   
Results: In the first analysis, 78.6 % (n=11) of subjects met the criteria for positive diagnosis of 
upper respiratory symptoms (URS) during the two week post-race period.  In four subjects (36.4 
%), URS appeared to be of inflammatory origin, but these were not linked to systemic markers of 
an allergic response.  Of the URS positive subjects, six (54.5 %) presented with markers of 
infection, three (27.3 %) with markers of a de novo infection and three (27.3%) with a profile 
suggestive of reactivation of previous infection.  Of those presenting with markers of infection 
66.7 % (n=4) had concomitantly elevated levels of sIgE suggestive of allergic response.  There 
was, however, no evidence of isolated allergic reaction independent of other causes amongst the 
symptomatic subjects.  
In the second analysis, 75% (n=12) of runners presented with post-race RTS and seven of these 
were Phadiatop® positive.  In four of the Phadiatop® positive RTS subjects, symptoms appeared 
to be of allergic origin.  Although total IgE concentrations were significantly higher (p< 0.01) in 
Phadiatop® positive group, there was no significant difference between the eosinophil and 
basophil concentrations or post-race RTS of the positive and negative groups (p>0.05).  Of the 
four subjects who did not develop RTS, three were Phadiatop® positive.  
 
Conclusion: Respiratory tract symptoms in trail runners have a multi-factorial aetiology.  A link 
between concurrent markers of an allergic response and infection is common in symptomatic 
trail runners.  The Phadiatop® assay does not accurately predict the incidence of allergic post-
exercise RTS in trail runners. 
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CHAPTER 1 – INTRODUCTION 
 
1.1  Background to the problem 
 
It has been noted since the early 1980’s that intensive exercise training and exhaustive endurance 
events result in an increased incidence of Upper Respiratory Tract Infections (URTI) in athletes 
(Peters and Bateman, 1983).  These symptoms interrupt training schedules and impair 
performance or readiness for competitive events.  For many years exercise immunologists have 
sought methods of identifying the cause of these symptoms (Walsh et al., 2011) and numerous 
theories have been examined in an attempt to explain them. 
 
As the majority of cases of post-exercise URTI symptoms are now known not be infectious in 
origin and may include conditions of the lower respiratory tract, the term, respiratory tract 
symptoms (RTS), is preferred current terminology (Schwellnus et al., 2010).  Studies have 
shown that only approximately one third of cases of post-exercise RTS are caused by infection, 
another third caused by a non-infectious (inflammatory) medical causes and the final third 
unknown etiology (Reid et al., 2004; Spence et al., 2007; Cox et al., 2008).  Other theories 
proposed to explain these non-infectious causes include systemic or run-away inflammatory 
response, reactivation of prior viral infection, development of hypersensitive airways and allergic 
response. 
 
Athletes experience higher rates of allergic diseases than the general population (Thomas et al., 
2010) and the cited incidence of allergy among Olympic athletes is steadily increasing (Weiler et 
al., 1998; Katelaris et al., 2003; Bonini et al., 2003).  A potential link between exercise and an 
up-regulation of the TH2 (allergic) side of the immune system was suggested by Smith as early as 
2003, while examining the cytokine response of the body to strenuous exercise and tissue 
trauma.  Allergies are typically associated with raised circulating concentrations of IL-4, IL-5, 
IL-10, and IL-13 and IgE and low concentrations of INFγ (Meischer and Vogel 2002; Neaville et 
al., 2003).  This TH2 dominant shift has also been associated with a higher incidence of allergies 
in athletes (Bonini and Craig, 2008).  Additionally, it has been demonstrated that atopy is a 
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major risk factor for hyper-reactive airways (HRA) and exercise induced asthma in athletes, and 
it has even been suggested that atopy is more common among athletes (Helenius et al., 1998; 
Langdeau et al., 2000).  It has also been proposed that repeated exposure to allergens or 
damaging pollutants increases the potential for allergic responses in athletes who are predisposed 
(Bonini et al., 2006).  
 
Numerous studies (Katelaris et al., 2003; Bonini et al., 2006; Bonini and Craig, 2008; Carlsen et 
al., 2008; Thomas et al., 2008) have highlighted the prevalence of allergic disease amongst the 
athletic population and recent reviews (Peters, 2004; Schwellnus et al., 2010) have included 
allergy as a possible contributor to post-exercise upper or lower respiratory tract symptoms. 
Furthermore, as allergic reactions can produce a range of upper and lower respiratory symptoms 
that closely mimic URTI (Schwellnus et al., 2010) and as exercise may up-regulate an allergic 
response in those already sensitized, allergic response should definitely be considered as an 
underlying factor in the development of post-exercise RTS.  This is further reinforced by recent 
findings of Schwellnus et al. (2011) who related the high incidence of pre-race RTS symptoms in 
triathletes to allergy. 
 
Thus, although there is still much debate as to the cause of a large percentage of post exercise 
RTS, and while the link between RTS and atopy has been proposed by a number of authors, 
more research is needed to support this.  A clear understanding of the underlying factors or a 
definitive test to identify those at risk may allow for the development of effective strategies to 
prevent post-exercise RTS. 
 
1.2 Aims and objectives of the study 
 
The primary objective of this field trial was to document the incidence of self- reported 
respiratory tract symptoms over a 31 day period (from 2 weeks before the race until 2 weeks 
after the race) in 22 athletes competing in the Three Cranes Challenge 2011, a three day 95 km 
trail run, in Karkloof, KwaZulu-Natal, and relate these to the general systemic and salivary 
immunological profile as well as atopic status of the participants.  A secondary objective was to 
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1) Due to the nature of the race (over multiple days and in a conservancy area including 
forests and grassland) there will be an increase in self-reported RTS in athletes during the 
two weeks following the event. 
 
2) The three-day trail run will result in cumulative effects on systemic markers of immune 
system activation.  
 
3) The incidence of RTS would not be related to one individual systemic or salivary marker 
of immune function.  
 
4) Atopic runners (diagnosed using the Phadiatop® assay), will present with raised markers 
of allergic activation. 
 
5) The Phadiatop® assay accurately predicts predisposition to RTS of allergic origin. 
 
 
1.4 Scope of the work 
 
A convenience sample of 22 (15 female, 7 male) subjects between the ages of 25 and 50 years, 
made up of entrants into the Three Cranes Challenge 2011, a 95 km trail run divided into three 
daily stages, in Karkloof, KwaZulu-Natal, volunteered to participate in this study.  Only 16 
subjects completed the in-race and post event testing, and a further two were excluded due to 
reliance on anti-histamine medication.  
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The athletes were required to document the incidence of self- reported RTS over a 31 day period 
(beginning 2 weeks before the race and ending 2 weeks after).  Blood samples were collected at a 
total of eight time-points, before and after each day’s stage, and at 24 hours and 72 hours post 
race.  Saliva samples were collected between 60-90 minutes before the start of the 1st stage of the 
race within 60 minutes following completion of the last stage of the race, and at 24 and 72 hours 
post race.  Outcome measures examined included incidence of RTS, pre-race Phadiatop® status, 
changes in concentrations of sIgE, cortisol, high sensitivity C - reactive protein (hs-CRP), 
differential leukocyte counts and sIgA. 
Two analyses of the data were conducted. In the first, the incidence of RTS was related to the 
detailed immunological profile of the athletes, in 14 case studies.  In the second, the validity of 









Athletes have a higher prevalence of respiratory symptoms than the general population 
(Hemingson et al., 2004; Verges et al., 2005) and upper respiratory tract infection (URTI) is the 
most common presenting complaint in sports medicine practices (Bermon, 2007).  URTI 
interfere with training schedules and impair performance (Gleeson, 2007). While it appears that 
moderate intensity exercise may reduce chances of contracting URTI over sedentary controls, 
increased concentrations of cortisol and catecholamines released during high intensity, prolonged 
exercise may have a perturbing effect on the immune system.  This has lead to the proposal of a 
‘J shaped curve’ where moderate exercise is associated with reduced risk of URTI and either no 
exercise or high exercise loads with increased risk (Nieman, 2003; Moreira et al., 2009).  
 
It has been determined that high intensity prolonged exercise results in increased plasma 
concentrations of IL-6, IL-10 and IL-1ra suggesting a shift in dominance of T helper cell type 2 
(TH2) over T helper cell type 1 (TH1) cells (Gleeson, 2007).  It is believed that the more 
dominant TH2 immune response after exercise, may up-regulate the actions of the humoral and 
allergic components of the immune system, and suppress the actions of the TH1 mediated, 
cellular immunity. This transient suppression of the TH1 cellular immunity has been implicated 
in the increased incidence of URTI infections in athletes after strenuous training or events 
(Peters, 2004; Bonini et al., 2006) and an “open window” of opportunity for infection of 3 to 
72hrs post exercise has been described (Peters, 2004).  Peters et al. (1993) demonstrated a 
significantly increased incidence of self reported URTI symptoms in a double blind placebo 
controlled study in a large group of runners after an ultra marathon.   
 
However, more recently, Spence et al. (2007) demonstrated that, although athletes displayed 
more symptoms of upper respiratory infection after competition or heavy training compared to 
controls (supporting the J shaped curve theory), pathogens were only isolated in 30% of cases. 
This has caused exercise immunologists to question whether other inflammatory or allergic 
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responses may be the cause of the increased reports of respiratory tract symptoms (RTS) noted 
after prolonged exercise (Peters, 2004; Schwellnus et al., 2010).  This uncertainty as to the exact 
cause of these symptoms has, more recently, lead to the terms Upper Respiratory Symptom 
(URS) or Respiratory Tract Symptoms (RTS) becoming the preferred terminology (Schwellnus 
et al., 2010; Walsh et al., 2010). 
 
The current state of the knowledge regarding the three main theories proposed to explain the 
development of exercise-associated RTS (namely infectious, inflammatory and allergic) will 





Numerous studies have demonstrated increased incidence of  URTI after exhaustive exercise 
(Peters and Bateman, 1983; Nieman et al., 1989; Peters et al., 1993) and this increased incidence 
has also been associated with periods of increased training load (Schwellnus et al., 2010).  The 
majority of the studies to date have used self reported symptoms and due to high costs of 
laboratory tests, the delay in receiving test results and the fact that physicians are rarely present 
in a research setting, very few of these studies verified the presence of infection (Walsh et al., 
2010).  Thus it is more correct to talk of URS or RTS where infection has not been confirmed. 
 
Furthermore, sports physicians are constantly endeavoring to differentiate between Upper 
Respiratory Tract Symptoms (URTS) including symptoms of the nose and pharynx, Lower 
Respiratory Tract Symptoms (LRTS) including chest symptoms and Systemic Symptoms (SS) 
including fever, myalgia, fatigue and headache (Schwellnus et al., 2010).  Although URTI or 
‘sore throats’ are the most frequent reason for athletes to visit the sports physician, most RTS 
reported in exercise immunology studies are of short duration (1 - 3days) and do not involve SS 




The incidence of RTS in elite athletes do not necessarily follow the expected seasonal pattern 
noted in the general population, but rather centre around high intensity training in some sports 
(e.g. swimming) or after competitions (e.g. endurance running) (Schwellnus et al., 2010).  Other 
more illness-prone athletes may also experience RTS during routine training periods or following 
increases in training schedules (Walsh et al., 2010).  
 
Confirming the findings of Spence et al. (2007), Cox et al. (2008) identified organisms in 30% 
of cases and categorized a further 27% as suggestive of infection, but with no identifiable 
organisms.  In conjunction with the findings of Reid et al. (2004) these studies also demonstrated 
that most positively identified infections are viral with only 5% of episodes caused by bacteria 
and that the causative organisms are those commonly associated with URTI in the general 
population.  These studies reported approximately one third of cases of RTS caused by infection, 
another third caused by a non-infectious/ inflammatory medical cause and the final third 
unknown etiology.  Furthermore, the diagnosis of infection by a sports physician (previously 
considered the gold standard) has been called into question and may not be the definitive test in 
determining RTS of infectious origin (Cox et al., 2008).  
 
However the commonly accepted hypothesis of an exercise induced immunosuppession still 
persists. This is based on the findings of numerous studies displaying the perturbing effect of an 
acute bout of strenuous exercise on various immunological parameters (Gleeson, 2007).  This is 
most likely as a response to the increased concentrations of stress hormones during exercise. 
Following exercise circulating lymphocyte counts are depressed below pre-exercise levels for a 
number of hours (Gleeson, 2007) and natural killer cell counts drops to less than half of pre-
exercise values (Shephard and Shek, 1999).  Furthermore neutrophils display a diminished 
response to bacterial stimulation and lymphocytes’ proliferative response to bacteria is 
diminished after an acute bout of exercise (Gleeson, 2007).  
 
The cytokine response to an acute bout of exhaustive exercise is well studied (Walsh et al., 
2010).  Cytokines are messenger chemicals found in plasma that are known to influence 
leukocyte function.  Exercise causes a shift in cytokine concentrations that is very similar to 
tissue trauma, burns or infection (Smith, 2004).  Typically exercise results in increases in 
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Interleukin- 6 (IL-6), IL-10, IL-1ra and Tumour Necrosis Factor Alpha (TNF α), whereas IL-2 
and Interferon Gamma (INFγ) are down regulated (Gleeson, 2007).  The release of these 
cytokines may be triggered by leakage of endotoxins from the intestines during exercise, 
elevation in circulating hormones (catecholamines and cortisol), raised body temperature, muscle 
damage, oxidative stress and glycogen deficiency (Nieman et al., 2005).  It has been noted that 
the particular pattern of cytokine imbalance is suggestive of a TH2 lymphocyte dominant 
response to this type of stress (Lakier Smith, 2003; Peters, 2004).  TH2 lymphocytes secrete IL-4, 
IL-5, IL-6, IL-10, IL-13 and TNF α, whereas TH1 lymphocytes secrete IL-2, IL-12, INFγ and 
TNFß (Smith, 2003).  TH1 lymphocytes are involved in cell-mediated immunity, while TH2 
lymphocytes are linked to humoral immunity. Therefore, this particular pattern of up regulation 
of TH2 cytokines and low or undetectable levels of TH1 cytokines is believed to indicate a 
transient suppression of cellular immunity by humoral immunity (Gleeson, 2007).  Additionally, 
the percentage of TH1 lymphocytes in circulation has been shown to decrease whereas the TH2 
lymphocytes remain the same (Lancaster et al., 2004).  These changes are most probably as a 
result of inflammation or increased cortisol concentrations.  The above argument was previously 
used to support the infectious theory and to explain what was perceived as an ‘open window’ for 
infection (increased incidence of URTI symptoms) 3 – 72 hours post exercise. 
 
However, recent reviews have found no significant link between changes in any single immune 
parameter (other than salivary IgA (sIgA)) and risk of RTS (Schwellnus et al., 2010, Walsh et 
al., 2010) and due to the complexity of the immune system, exercise immunologists have over 
the past few decades experienced difficulty in finding a single, reliable outcome measure to 
successfully measure immune suppression or susceptibility to disease.  The only immunological 
parameter that has demonstrated a consistent relationship with RTS in athletes is concentration 
and secretion rate of sIgA which is commonly used as a marker of mucosal (or first line) 
immunity (Walsh et al., 2010).  The effect of exercise on secretion rate and concentration of 
SIgA is dependent on exercise intensity, with prolonged, high intensity exercise typically 
resulting in decreases in sIgA and shorter, lower intensity exercise causing moderate increases in 
SIgA.  Walsh et al. (2010) state that there is a consistent association between decreased 
concentration or secretion rates of SIgA and increased risk of RTS or URTI in elite athletes.  
While Neville et al. (2008) determined in a large 50 week prospective study, that a decrease in 
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sIgA concentration of more than 40% from healthy baseline resulted in a one in two chance of 
developing an upper respiratory infection within the next 3 weeks. 
 
A small proportion of elite athletes develop a syndrome consisting of repeated (frequent) RTS, 
chronic fatigue and poor performance.  Reid et al. (2004) when studying a group from this 
population, displayed a high percentage of reactivation of Epstein Barr Viral (EBV) infections, 
and Gleeson et al. (2002) also demonstrated reactivation and a significant relationship between 
EBV sero-positive status and development of RTS.  This has lead to the development of the viral 
reactivation theory for the aetiology of post-exercise RTS (Walsh et al., 2010), this is supported 
by the fact that many RTS are of short duration and therefore not new infections, but rather 
related to chronic unresolved viral infection that may be reactivated by the stress of exercise 





Under normal conditions, the airways condition inspired air, filtering, warming and humidifying 
it, thereby protecting the lower airway.  This process is dependent on the nasal mucosal blood 
vessels and glands, which are under autonomic control (Bonini et al., 2006; Swartz et al., 2008).  
Hyperpnoea resulting from prolonged exercise results in water loss from respiratory mucous 
membranes, which in turn puts the stress of conditioning the air onto the smaller bronchioles.  
This results in a ‘dehydration injury’, which causes a type of airway sensitivity called hyper-
reactive airways (HRA) (Anderson and Kippelen, 2008).  Athletes are particularly susceptible to 
this mucosal drying, which occurs regularly over a training season, and results in airway changes 
such as increased numbers of neutrophils, eosinophils and lymphocytes noted at rest, 
demonstrating a lingering or chronic inflammatory process (Bermon, 2007; Anderson and 
Kippelen, 2008).  HRA is aggravated by cold dry air and chronic inhalation of allergens and/or 
irritant particulate matter, and hence certain sports exposed to these factors show higher levels of 
sensitive individuals.  These sports include swimmers (exposed to chlorine), endurance runners 
(allergens and pollutants), and cross country skiers (cold air inhalation) (Rundell and Jenkinson, 
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2002; Bermon, 2007).  The pathogenesis of this hypersensitivity is believed to start with 
dehydration injury and changes in the osmolarity of the airway cells.  The resultant influx of 
water to correct this imbalance is believed to stimulate the release of inflammatory mediators, 
potentially stimulating bronchoconstriction, vasopermeability and mucus hypersecretion 
(Bermon, 2007; Swartz et al., 2008).  It is believed that, as water loss from the airways is 
common to all who exercise, the ability to return moisture to the dehydrated mucosal surface 
must be different between healthy and inflamed airways (Andersen and Kippelen, 2008).  An 
alternative explanation for HRA states that temperature changes stimulate bronchial airway 
narrowing and that at the end of the exercise the rapid re-warming results in a reactive hyperemia 
that causes further bronchospasm (Rundell, 2002).  It is likely that mast cells are important in the 
pathogenesis of hypersensitivity. Mast cells release bronchoconstrictor mediators such as 
histamine, cysteinyl leukotrines and prostaglandins following exercise (Carlsen et al., 2008).  
Sensitized airway smooth muscle may be infiltrated with mast cells and increased numbers of 
mast cells have been found in the airway smooth muscle of both asthmatic and healthy athletes 
(Anderson and Kippellen, 2008). 
 
Many studies show increased numbers of inflammatory cells in broncho-alveolar lavage fluid of 
endurance athletes (Bermon, 2007).  For example increased T-lymphocytes, neutrophils, 
eosinophils and macrophages in cross-country skiers, runners show increased neutrophilia, 
swimmers show neutrophilia but no eosinophilia (Bermon, 2007).  Rong et al. (2008) 
demonstrated significantly higher levels of neutrophils and macrophages in the saliva of 
swimmers at rest, compared to controls, indicating airway inflammation.  However findings have 
not always been consistent, with some studies displaying neutrophilia without eosinophilia and 
vice versa (Parsons et al., 2008).  It should be noted that healthy control subjects rarely exhibit 
sputum eosinophilia (Helenius et al., 2005).  In spite of the elevated numbers of inflammatory 
cells, markers of inflammation such as eosinophil peroxidase and neutrophil lipocain are 
generally normal (Bermon, 2007).  As neutrophils are attracted to the airway by inflammatory 
mediators (IL-8, IL-1B, TNF-a, leucotrines etc.) (Bush, 2010), it is believed that this increased 
cellularity could represent systemic as opposed to local inflammation, as an absence of local 
neutrophil activation has been noted along with decreased expression of eosinophil and 
macrophage surface adhesion molecules.  Therefore, the concept of “blunted” or “frustrated” 
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inflammation has been suggested (Bermon, 2007).  However it may be possible that under 
certain conditions, a loss of control of this inflammation may occur, resulting in an acute airway 
inflammation causing similar symptoms to URTI. Cox et al. (2007) when comparing the post 
exercise inflammatory responses of healthy and illness prone athletes found that the illness prone 
athletes displayed an altered state of inflammatory control and a potential for excessive 
inflammation.  Furthermore, structural changes such as lymphoid aggregates and basal 
membrane changes have also been observed on bronchial biopsies of cross country skiers 
(Bermon, 2007). 
 
However, experiments such as those of Cox et al. (2010) using local anti-inflammatory agents 
(Difflam throat spray) are open to interpretation.  The incidence of RTS events was not reduced 
but the severity of symptoms was lessened by the intervention suggesting that the reaction does 
not just involve local factors but rather systemic inflammatory markers (Cox et al., 2010). 
 
2.4 Other non-infectious causes 
2.4.1. Airway Hypersensitivity 
 
There are numerous factors that contribute to hypersensitivity in the airways and these 
hypersensitive states can lead to a sensitization or respiratory hyper responsiveness to additional 
stimuli, such as exercise.  This could potentially produce RTS or conditions such as hyper-
reactive airways (HRA) or exercise induced bronchospasm (EIB), a form of non-allergic asthma.  
Aetiological factors include chronic or repeated exposure to cold or dry air as seen in cross-
country skiers (Langdeau et al., 2000; Hemingson et al., 2004), exposure to allergens, for 
example in endurance runners (Bonini et al., 2006; Schwellnus et al., 2010) and exposure to 
various pollutant irritants, which may affect a number of different sports people.  Examples of 
pollutant irritants include chlorine, which may explain the high incidence of upper and lower 
airway symptoms, EIB and asthma in elite swimmers (Langdeau et al., 2000).   Sulphur dioxide, 
from the breakdown of fossil fuels (smog). When dissolved in the surface fluids of the lung 
sulphur dioxide yields sulphuric acid and other irritants, which damage epithelium and stimulate 
the release of inflammatory mediators.  This may contribute to wheeze, tight chest, cough and 
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sputum in HRA or asthmatic subjects (Bonini et al., 2006).  Particulate matter are small particles 
in the air (< 10m) that are deposited in the lower airways, these acidic particles may aggravate 
respiratory symptoms and decrease lung function by activating leukotrines and stimulating 
inflammation (Rundell et al., 2003; Bonini et al., 2006).  Particulate matter may also act as an 
attractant for neutrophils (Andersen and Kippelen, 2008).  Chronic exposure to ozone is also 
known to cause respiratory symptoms and decreases in lung function. Ozone may also result in 
transient airway hyper-responsiveness, and nasal and lung allergen responsiveness is increased 
by ozone.  Nitrogen dioxide from motor vehicles does not affect healthy individuals but in 
asthmatics this enhances airway responsiveness (Bonini et al., 2006).  Thus certain sports might 
put people at risk of chronic exposure to these irritants and increase the possibility of airway 
hyper reactivity or inflammation.  Research has indicated a gender difference in HRA in athletes, 
with women showing a significantly higher prevalence than men.  It is hypothesized that this 
may be due to the smaller diameter of women’s airways (Langdeau et al., 2009).  Carlsen, (2009) 
found that the incidence of bronchial hyper-responsiveness (BHR) increased with age and 
duration of training.  This finding was also confirmed by Pedersen et al. (2009) in their study on 
HRA in adolescent swimmers. These factors are also believed to contribute to the development 
of non-allergic rhinitis (NAR) a condition that mimics allergic rhinitis in symptomatology, but 
presents with normal serum (Bousquet et al., 2008).  
 
 
Under normal circumstances exercise improves nasal efficiency and results in a reduction of 
nasal resistance of up to 50% due to an increase in nasal sympathetic tone and vasoconstriction 
(Bonini et al., 2006).  However, cold air induces glandular secretion and nasal discharge in 
normal subjects, a response that is exaggerated in rhinitics.  Swimmers are prone to a chemical 
sensitivity known as ‘chloride treated water allergy’ characterized by nasal obstruction, watery 
nasal discharge and sneezing (Bonini et al., 2006) which may predispose swimmers to rhino-
sinusitis, rhino-otitis and asthma.  Divers are prone to barometric rhino-sinusitis due to repeated 
sudden pressure changes (Bonini et al., 2006).  Another non-allergic type of rhinitis is seen in 
cold weather endurance athletes and is commonly known as ‘skier’s nose’.  This vasomotor / 
non-allergic rhinitis occurs when cold temperatures trigger a parasympathetic reflex resulting 
initially in nasal discharge and later in nasal congestion due to the dilation of the turbinate 
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vessels and increased mucus transport times (Bonini et al., 2006).  Finally, some predisposed 
individuals appear to experience excessive drying of the rhinosinusal mucosa in response to 
prolonged exercise.  This leads to thickening of nasal secretions and increased muco-cillary 
transport times, and also promotes a rebound increase in nasal secretion and repeated bouts of 
watery rhinorrhea commonly called ‘runners nose’ (Bonini et al., 2006).  It is conceivable that 
the mucus membrane damage caused by thermal, osmotic or irritant stimuli, and its resulting 
inflammation, may sensitize the individual and increase the likelihood of developing further IgE 
mediated allergies. 
 
Lower airway hypersensitivity is evident in cold weather athletes where it is commonly known 
as ‘ski asthma’.  Symptoms include coughing, wheezing tight chest, dyspnoea and excessive 
mucus production (Rundell and Jenkinson, 2002).  It is believed that oedema and excessive 
mucus production could amplify the bronchoconstriction seen in cold weather athletes and 
account for the pathogenesis of ‘ski asthma’ and the increased incidence of respiratory symptoms 
seen in these athletes (Anderson and Kippelen, 2008, Carlsen et al., 2008).  Thus the airway 
hyper-responsiveness evident here would be the result of airway injury rather than a sign of 
classic asthma (Bonini and Craig, 2008). 
 
Exercise induced bronchospasm (EIB) is the term used to denote the airway hyper-reactivity 
observed in non-asthmatic, non-atopic populations (Rundell and Jenkinson, 2002).  Although 
bronchoconstriction is common in asthmatics EIB affects the athletic population as a whole, with 
research showing a prevalence of 50% in athletes (Rundell and Slee, 2008; Parsons et al., 2008).  
Parsons et al. (2008) demonstrated increased concentrations of inflammatory mediators in the 
airways (sputum) of non-asthmatic athletes who experienced EIB after exercise, this finding that 
was confirmed in the research of Verges et al. (2005).  Significant differences in concentrations 
of cystinal-leucotrines, leucotrine B4, thromboxane B2, and prostaglandin E2 were noted in 
athletes after eucapnic voluntary hyperventilation to induce EIB (Parsons et al., 2008).   
Neutrophlia in the lower airways of endurance athletes may be the result of airway injury, or due 
to the increased incidence of viral infections in this population.  In athletes exposed to viral 
infections, allergens, irritants and particulate matter, there may be activation of other innate 
immune mechanisms rather than IgE.  Therefore this may be a type of ‘neutrophilic’ as opposed 
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to eosinophilic asthma (Anderon and Kippelen, 2008).  It has also been demonstrated that high 
intensity exercise results in increased markers of pulmonary epithelial permeability.  This 
disruption of the epithelial barrier has been implicated in the development of asthma in athletes 
as a result of exposure to pulmonary irritants (Anderson and Kippelen, 2008).  Finally injury to 
the epithelium may expose sensory nerve endings to foreign particle or endogenous 
inflammatory mediators.  It is hypothesized that EIB in cold weather athletes could be partly 
triggered by neuropeptide from stimulated sensory nerves (Anderson and Kippelen, 2008) and 




Allergy has also been proposed as a possible cause of non-infective RTS.  In fact, the exercise-
induced TH2 / TH1 dominance cytokine pattern is one now commonly associated with the 
development of allergies and asthma.  Allergies are typically associated with raised IL-4, IL-5, 
IL-10, and IL-13 and low INFγ, and are also associated with high serum IgE (sIgE) 
concentrations (Meischer and Vogel, 2002; Neaville et al., 2003).  Rong et al. (2008) 
demonstrated raised serum concentrations of IL-4 and lower concentrations of IL-10 in a 
population of Chinese professional athletes when compared with controls.  Swimmers and 
endurance athletes demonstrated the highest concentrations of IL-4, as well as the greatest 
indices of small airway dysfunction.  Il-4 is a TH2 cytokine and is known to up-regulate the IgE 
receptors on B lymphocytes, hence contributing to the inflammatory response resulting in 
asthma. Il-10 exerts an opposite anti-inflammatory effect.  This finding was supported by an 
earlier animal study by Davis et al. (2005), who demonstrated that cold air exercise in horses 
produced a predominantly TH2 cell dominant pattern of cytokine production in bronchoalveolar 
lavage fluid.  Significantly higher concentration of IL-4, IL-5 and IL-10 were noted, along with a 
lesser up-regulation of IL-2 and IL-6. It was proposed that this shift was a result of mast cell 
activation due to airway cooling and desiccation, and hypothesized that this mechanism may be 




The TH2 dominant shift has also been associated with a higher incidence of allergies in athletes 
(Bonini and Craig, 2008).  Certainly, it has been demonstrated that atopy is a major risk factor 
for HRA, EIB and exercise induced asthma (EIA) in athletes, and it has even been suggested that 
atopy is more common among athletes (Helenius et al., 1998; Langdeau et al., 2000).  Kyllonnen 
et al. (2006) demonstrated that patients with atopic dermatitis produced more respiratory 
symptoms, HRA and sputum eosinophilia than controls.  It has also been suggested that airway 
injury and increased mucosal permeability may promote the development of asthma, particularly 
in predisposed (atopic) individuals (Anderson and Kippelen, 2008) and that repeated exposure to 
damaging pollutants increases the potential for allergic responses in the predisposed (Bonini et 
al., 2006).  This is supported by the findings of Aldred et al. (2010) who demonstrated a 
significant elevating effect of steady state exercise on sIgE concentrations of individuals with 
prediagnosed allergies. 
  
Eosinophilia is a characteristic of most allergic disorders (Morris, 2009).  T cell mediated 
eosinophilia is mostly driven by TH2 T cells, with IL-5 being the most important cytokine for 
differentiation and activation of eosinophils (Simon and Simon, 2007).  It is possible certain 
eosinophilic, allergic reactions may be triggered by IL-5 releasing T cells being stimulated by 
atypical means e.g. infective or autoimmune.  Additionally, a subgroup of allergic rhino 
conjunctivitis, asthma and dermatitis (known as ‘intrinsic’) are not driven by IgE mediated 
pathways, although the eosinophilia seems to be similar and also driven by IL-5 releasing TH2 
cells (Simon and Simon, 2007).  
 
It has been documented that athletes experience higher rates of allergic diseases than the general 
population (Thomas et al., 2010) and that the cited incidence of allergy among Olympic athletes 
is steadily increasing (Weiler et al., 1998; Katelaris et al., 2003; Bonini et al., 2006).  As allergic 
reactions can produce a range of upper and lower respiratory symptoms that closely mimic URTI 
(Schwellnus et al., 2010) and as exercise is known to induce a TH2 dominant immunological 
shift, it is proposed that exercise may up-regulate an allergic response in those already sensitised 
(Lakier Smith, 2003), and an increased exposure of athletes to irritants and allergens (Bonini et 
al., 2006; Schwellnus et al., 2010) may contribute towards this. Recently, Schwellnus et al. 
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(2011) related the high incidence of pre-race RTS symptoms documented in triathletes to allergy 
rather than any other factor. 
 
Although  the skin prick test (SPT) is generally accepted as the standard method for detecting IgE 
related allergic sensitization (Vidal et al., 2005) and is cheaper, faster and has less false positives 
than specific IgE antibody testing used in the Phadiatop® assay (Morris, 2009) it does have 
certain limitations.  These include lower response in the elderly, greater difficulty in grading the 
response in darkly pigmented persons, contraindication for the pregnant, the quality and selection 
of allergens, theoretical risk of anaphylaxis and operator inexperience (Antunes et al., 2009; 
Morris, 2009) which may hinder its application.  
 
Specific IgE antibody testing is accepted as an alternative to the SPT and combination tests exist, 
such as Phadiatop® assay (Pharmacia & Upjohn Diagnostics, Uppsala, Sweden) which 
simultaneously test for IgE to a mixture of allergens causing common inhalant allergies.  
Allergens included in the Phadiatop® assay are Artemisia, dust mites (D. pteronyssinus and D. 
fariane), mixed moulds (Penicillium, Cladosporium, Aspergillus and Alternaria), pet dander (cat 
and dog), mixed grasses (Parietaria, Lolium, Phleum and Cynodon), and mixed trees (Acer, 
Betula, Olea, Salix, Pinus, Ulmus, Quercus, Eucalyptus, Acaciaand Malaleuca) (Garcia-Marcos, 
2007). 
 
The Phadiatop® assay has not only been found to offer satisfactory accuracy for diagnosing of 
IgE allergic sensitization in the general population (Vidal et al., 2005), but has also been used 
previously in exercise immunology as part of an assessment of atopy in athletes (Moreira et al., 
2007) during the Helsinki city marathon.  Vidal et al. (2005) found a sensitivity of 70.8% and a 
specificity of 90.7% compared to the SPT. They also displayed a 6.9% false positive rate and a 
7.5% false negative rate compared to SPT.  Garcia-Marcos et al. (2007) displayed a rate of false 
positives of 10% and found that the lower the rate of atopy in a population the higher the rate of 
false positives.  However, the allergens included in the Phadiatop® assay are fixed and cannot be 





Allergic rhinitis occurs commonly in athletes, with 16.8% of athletes suffering from hay fever 
(Bonini et al., 2006).  Rhinitis and asthma are connected, with allergic rhinitis increasing the risk 
of other airway symptoms. The link between allergic rhinitis and asthma is further reinforced by 
the fact that controlling rhinitis leads to better control of asthma (Serrano et al., 2004; Bonini et 
al., 2006; Schwartz, 2008).  It is also believed that the incidence of allergic rhinitis is increasing, 
in 1980, 8% of Olympic athletes were found to have clinical rhinitis and the figure had doubled 
(16.9%) by 1996 (Bonini et al., 2006). Another study found that of 214 athletes from 12 Olympic 
sports disciplines, 56% suffered from allergic rhino conjunctivitis and 41% had both symptoms 
and a positive skin prick test (Carlsen et al., 2008).  Nasal inflammation in allergic rhinitis is 
accompanied by a significant increase in eosinophils in the epithelium and nasal lamina propria, 
as well as increased IL-5 and other inflammatory cytokines in the sputum (Serrano et al., 2005). 
Allergic rhinitis has been shown to negatively affect the ability of athletes to train and compete, 
and athletes on treatment with intranasal steroids showed increased performance scores (Bonini 
et al., 2006).  Carlsen et al. (2008) report that the cited rate of allergic rhinitis in athletes is 
clearly higher than in the normal population. 
 
Asthma is defined as a chronic inflammatory disease of the respiratory tract in which a number 
of cells play a role including mast cells, eosinophils and T Lymphocytes.  It leads to increased 
HRA, dyspnoea, wheezing, cough and shortness of breath (Bonini et al., 2006).  EIB and 
exercise induced asthma (EIA) are similar, but EIB is a term used in non-asthmatics and EIA is a 
term reserved for broncho-constriction in asthmatics (Carlsen et al., 2008).  Not all asthmatic 
subjects experience EIA, it appears to be a common, but discrete clinical phenotype (Hallstrand 
et al., 2005) that shows increased concentrations of epithelial cells, eosinophils, cysteinyl 
leukotrines and decreased PGE2 in sputum compared to non EIA asthmatics (Hallstrand et al., 
2005).  The similarities between these findings and the findings of other studies on non-
asthmatic EIB positive athletes are interesting and raises the likelihood of chronic exercise 
induced HRA, leading to EIB and eventually possibly resulting in asthma (Davis et al., 2005).  
HRA and asthma are significantly more common in cross country skiers when compared to 
healthy control subjects (Helenius et al., 1998; Davis et al., 2005).  The occurrence of asthma in 
elite athletes is on the increase, statistics indicated that 9.7% of athletes in the 1976 Olympics 
were asthmatic, this increased to 21.9% of athletes in 2000 Sydney Olympics (Bonini et al., 
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2006; Carlsen et al., 2008).  Asthma is also more common in elite athletes than in age matched 
controls (Bonini et al., 2006).  Asthma and allergic rhinitis often co-exist, with 80-90% of 
asthmatics suffering from rhinitis and 19-38% of rhinitics suffering from asthma (Serrano et al., 
2004; Bonini et al., 2006). 
 
Atopy is a major risk factor, together with the type of training, for an athlete developing asthma 
(Helenius et al., 1998).  The relative risk of developing asthma is increased by 25 times in atopic 
speed and power athletes, and increased by 75 times in atopic endurance athletes, when 
compared to non-atopic controls (Schwartz et al., 2008).  Mild asthma (when defined as 
bronchial hyper-responsiveness (BHR) to histamine or metacholine challenge) is most common 
in endurance athletes, with the highest numbers prevalent among cross country skiers (14.4 - 
54.8%), swimmers (13.4% - 44%), and long distance runners (14.8% - 19%) and track and field 
athletes (16.3%) (Helenius et al., 2005).  It is believed that the remodeling seen in the basement 
membranes of athletes with mild asthma could diminish their capacity to respond to evaporative 
water loss, and therefore increase susceptibility to dehydration injury (Rundell and Jenkinson, 
2002). 
 
The chronic eosinophilic inflammation seen in the lower airways of asthmatics may lead to 
airway remodeling such as epithelial desquamation, loss of tight junctions, metaplasia of 
epithelial goblet cells, thickening of the reticular basement membrane, hypertrophy of airway 
smooth muscle, fibrosis of the subepithelium, an increase in mucus glands as well as increased 
angiogenesis (Tsurikisawa et al., 2010).  The extent of the remodeling has been linked to the 
duration and severity of the asthma and the serum levels of IgE (Tsurikisawa et al., 2010).  
Airway remodeling has also been linked to BHR and long term decline in lung functions of adult 
asthmatics (Tsurikisawa et al., 2010).  Another interesting finding that may be relevant to 
asthmatic athletes is the relationship between neutrophilic inflammation in the airways of stable 
asthmatics and a lack of airway hydration, as demonstrated by Loughlin et al. (2009).  Due to the 
fact that airway dehydration has been implicated in airway injury and HRA, asthmatic athletes 
may be more susceptible if their airways are already less hydrated.  It has also been suggested 
that this airway dehydration may be the cause of the bronchoconstriction and mucus build-up 




2.4.3. Non-allergic Rhinitis 
 
Non-allergic rhinitis (NAR) is a condition characterized by symptoms similar to allergic rhinitis, 
such as anterior or posterior nasal discharge, sneezing, nasal obstruction and irritation, but 
presents with normal serum IgE levels and a negative skin prick test or Phadiatop® test for atopy 
(Wedback et al., 2005).  The prevalence in the adult population is believed to be at least 25% 
(Bousquet et al., 2008).  Although the exact cause is unknown the underlying mechanisms that 
have been postulated include environmental triggers (irritant pollutants); persistent inflammatory 
mechanisms; auto-immune dysregulation and neurogenic mechanisms (Bousquet et al., 2008).  
The airways of athletes may be exposed to a variety of increased stressors that may predispose 
them to this type of disorder.  Repeated dehydration injury, irritant pollutant and allergen 
exposure, cortisol and catecholamine fluctuations and temperature extremes may all contribute to 
the development of such well known, non-allergic and exercise related entities as “skiers nose”, 
“runners nose” and “chloride treated water allergy” (Bonini et al., 2008).   The diagnosis of NAR 
is based on the exclusion of criteria such as allergy and infection, rather than on condition 




Therefore, there is sufficient evidence to indicate that not all cases of post-exercise RTS are the 
result of infection, and while numerous studies provide evidence for an inflammatory aetiology, 
in a large percentage of cases the cause remains unknown.  Although certain non-infectious 
mechanisms have been proposed and while the incidence of allergic diseases in athletes is 
increasingly well documented, the relationship between allergic reaction and the development of 
post-exercise RTS has not been well explored.  Specifically, the contribution of allergic reaction 
to the incidence of post-exercise RTS in trail-runners in a rural environment is an area where 
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Objectives: To document the incidence of upper respiratory tract symptoms (URS) for two 
weeks before and two weeks after a three-day trail run and relate these to the general systemic 
and salivary immunological profile as well as atopic status of the participants.  
 
Study Design and Methods: A descriptive field study was conducted at the Three Cranes 
Challenge Trail run, a multi-day 95 km event divided into three stages, in Karkloof, KwaZulu-
Natal.  Fourteen runners were monitored over a 31 day period before and after the race.  Main 
outcome measures included the incidence of URS, Phadiatop® status, changes in concentrations 
of serum IgE, cortisol, high sensitivity C - reactive protein (hs-CRP), differential leukocyte count 
and sIgA. 
 
Results: Eleven of 14 subjects (78.6 %) met the criteria for positive diagnosis of URS during the 
14 days post-race. In four of the symptomatic subjects (36.4 %), URS appeared to be of 
inflammatory origin, but these were not linked to systemic markers of an allergic response.  Six 
(54.5 %) of these symptomatic subjects presented with markers of infection, three (27.3 %) with 
markers of a de novo infection and three (27.3%) with a profile suggestive of reactivation of 
previous infection.  Four (66.7 %) of those presenting with markers of infection had 
concomitantly elevated levels of serum IgE suggestive of allergic response.  There was no 
evidence of the isolated presence of an allergic reaction among the symptomatic subjects.  
 
Conclusion: URS in trail runners has a multifactorial aetiology. A link between concurrent 





It is well documented that athletes have a higher prevalence of respiratory symptoms than the 
general population.1,2 with upper respiratory tract infection (URTI) being the most common 
presenting complaint among elite athletes in sports medicine practices.3 Although 
epidemiological studies have confirmed increased incidence of self reported URTI symptoms 
after exhaustive exercise,4 few of these symptoms are likely to have been caused by infection.5 
Clinical studies have reported that approximately one third of cases of URTI symptoms are 
caused by infection6-8 with another third caused by a non-infectious medical conditions and the 
final third of unknown aetiology.5 This has lead to the preferred current use of the broader term, 
upper respiratory symptoms (URS).5 
 
A number of hypotheses have arisen in an attempt to explain the development of non-infectious 
URS such as an inflammatory response,3 reactivation of prior infection8 and airway 
hypersensitivity.9,10 The cytokine response to prolonged exercise has been hypothesised to result 
in an alteration in immune function which may predispose an individual to the development of 
allergies.11 More recently, an actual association between  responsiveness to allergens and the 
development of URS in athletes, has been proposed.12  
 
Furthermore, contributors to variants of non-allergic rhinitis (NAR)  which involve concomitant 
hypersensitivity and inflammation in the airways, include chronic or repeated exposure to dry 
air1, prolonged hyperventilation, increased environmental exposure to inhaled allergens such as 
pollens13 or various pollutant irritants which could stimulate the release of inflammatory 
mediators and result in hyper reactive airways (HRA) in endurance runners.9,13 Although airway 
changes such as increased numbers of neutrophils, eosinophils and lymphocytes, demonstrating a 
lingering or chronic inflammatory process,3,9 have been reported at rest, markers of activation of 
these immune cells are typically lacking, leading to the description of a state of ‘blunted’3 or 
‘frustrated’10 inflammation. These conditions which mimic allergic rhinitis, present with normal 
serum IgE levels.13 
 
There is therefore still much debate regarding the aetiology of a large percentage of post exercise  
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URS and the possible interactions between infectious, inflammatory and allergic origins remain 
unexplored. As a clearer understanding of the underlying factors may allow effective 
preventative strategies to be developed, the overall aim of this study was to conduct individual 
case studies describing the general immunological profile of 14 athletes taking part in a three-day 
95 km trail running event and relate these to the self-reported incidence of URS.  The specific 
aims were to i) determine the atopic status of each subject, ii) measure the concentrations of 
serum IgE, cortisol, high sensitivity C- Reactive Protein (hs-CRP) as well as differential 
leukocyte and secretory immunoglobulin A (sIgA) concentration throughout and after the event 




Approval to conduct this research was obtained from the Bioethics Committee of the University 
of KwaZulu-Natal.  This study formed part of a larger, more comprehensive work examining 
physiological responses of athletes who had registered for the Three Cranes 95km three-day trail 
run in Karkloof, KwaZulu-Natal which involved completion of 27.8, 37.9 and 29.3 km on days 
1, 2 and 3, respectively.  
 
A convenience sample of 22 (7 male, 15 female) volunteers between the ages of 25 and 50 years, 
were asked to sign an informed consent form (Appendix B).  In order to qualify for this study, 
runners needed to complete all three stages of the race and be free of any medical condition that 
could place their health at risk. Further exclusion criteria included smoking, the use of oral or 
inhaled anti-histamines or corticosteroids and the use of performance enhancing drugs. 
 
Baseline assessments included basic anthropometric measurements and vital signs at registration 
on the day before the race; blood sampling commenced the morning prior to the race. Blood 
samples were collected at eight time-points (Figure 1); before and after each day’s stage, 24 
hours post race and 72 hours post race. Saliva samples were collected between 60-90 minutes 
before the start of the race/Stage 1 (S1pre), within 60 minutes following completion of the race/ 
Stage 3 (S3post), 24 hours (24PR) and 72 hours post race (72PR).  The athletes were also 
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requested to document their experience of URS over a 31 day period, viz. during the 14 days 
prior to the start of the race, on each day of the race and during two weeks following the race.  
 
 
Figure 1. Time line of blood, saliva and URS sampling during the study     
14PRE = 14 days prior to the race; S1pre = prior to the start of stage 1 of the race; S1post = immediately after finishing 
stage 1 of the race; S2pre = prior to the start of stage 2 of the race; S2post = immediately after finishing stage 2 of the 
race: S3pre = prior to the start of stage 3 of the race; S3post = immediately after finishing stage 3 of the race: 24PR = 
24 hours after the finish of the race: 72PR = 72 hours after the finish of the race. 14POST = 14 days after the finish 
of the race; URS = upper respiratory symptom questionnaire; B = Blood Sample; S = Saliva Sample. 
 
Of the 22 subjects who started the study, two subjects were excluded from the study due to injury 
and illness, and a further four were unable to attend the post race sampling sessions. Of the 
remaining 16 volunteers who completed all three stages of the race and complied with all 
protocol requirements, a further two were excluded due to the use of the anti-histamine 
medication. 
 
Athletes were asked to record a detailed log of their self reported URS incidence and severity 
according to a 1 – 3 point scoring system over the two weeks prior to the start of the race 
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(Appendix C).  During the race further information was elicited each day pre and post stage. A 
post race URS questionnaire was used to record the incidence and severity of any URS over the 
two-week period following the race. The severity-ratio of each symptom used in the 
questionnaires was calculated from the sum of the above mentioned severity scores, divided by 
the number of days the symptom presented. A global symptom severity score was then 
determined by multiplying the severity ratio for each symptom by the duration of the illness. In 
an attempt to exclude symptoms of a trivial nature or not specific to the URT, a single URS 
lasting < 2 days and any non-specific symptom not accompanied by a URT symptom lasting > 1 
day, were omitted. 
 
Saliva collection took place via passive drool on subjects in the seated position with their head 
tilted slightly forward and minimal orofacial movement. After swallowing the saliva collected 
during the first minute, saliva samples were collected for four minutes in pre-weighed 
polypropylene microvials. Weighed tubes were then placed in a freezer (- 20oC) and later stored 
at - 80⁰C until analysis. The saliva volume was calculated from pre- and post- mass difference 
and saliva flow rate (ml.min-1) was determined by dividing this by the collection time. 
 
Concentration of sIgA (μg IgA x ml-1) was determined using an indirect enzyme immunoassay 
kit (Salimetrics, State College, USA). Salivary IgA secretion rate (μg sIgA x min-1), or the total 
amount of IgA appearing on the mucosal surface per time unit, was calculated by multiplying 
sIgA concentration by saliva flow rate.  
 
Venous blood samples were obtained at each of the eight testing periods from the antecubital 
vein of each subject in the seated position. Complete blood counts were measured on an Advia-
120 Hematology Analyzer (Siemens Healthcare Diagnostics, Deerfield, IL) at a commercial 
pathology laboratory (Ampath Laboratories, Howick). Extracted serum was immediately frozen 
in dry ice and transported to the laboratory for the determination of serum IgE, hs-CRP, cortisol 
and Phadiatop® assay. The latter, which measures concentrations of specific IgE antibodies 
towards a pre-determined selection of inhalant allergens14 was run using an automated UniCAP 




Plasma volume (PV) changes were determined from pre- and post-exercise haematocrit and 
haemoglobin concentrations according to the method of Dill and Costill.15 All concentration 
dependant, post stage blood cell parameters (IgE, leukocyte counts, cortisol, and hs-CRP values) 
were then adjusted for percentage change in PV. 
 
Statistics 
The majority of data are presented individually for each case study. In terms of the grouped data 
of the cohort (n=14), the abnormal distribution was confirmed using the Kolmogorov–Smirnov 
test and they are expressed as median (range). After logarithmic transformation, a generalized 
linear model was used on the grouped data for each parameter tested to identify any significant 
group or time effect. Statistical analysis was performed using SPSS version 18 (SPSS Inc., 
Chicago, USA) and significance was set at p=0.05. 
 
RESULTS 
The physical characteristics and results of baseline testing of the 14 subjects (10 female and 4 
male) are shown in Table 1. Minimum temperature at the start of the stages ranged from 11.5º C 
(S1) - 12.4º C (S3), whereas maximum temperature ranged from 21.2 º C (S3) - 22.8 º C (S2). At 
no stage did the wind speed exceed 2.8 m/s nor did it rain. A maximum relative humidity of 97% 
was recorded during S2.    
 
Table 1: Median (range) physical characteristics of the subjects (n=14). 
 
 Subjects (n=14) 
Variable Median  Range 
Age (years) 42.5 20.0 - 50.0 
Stature (cm) 168.0 158.0 - 184.0 
Mass (kg) 62.4 49.1 - 90.6 
BMI 23.3 19.7 - 27.7 
% Body Fat* 21.8 15.7 - 30.6 
Resting Heart Rate 57.5 49.0 - 66.0 
Resting Systolic BP 122.5 117.3 - 138.5 
Resting Diastolic BP 81.9 72.0 - 93.3 






The changes in median (range) of selected red blood cell indices reflect a drop in median (range) 
of haematocrit and haemoglobin concentrations and rise in percentage plasma volume (% PV) 
calculated for each stage over the course of the 3 day event and versus S1pre as baseline. Median 
(range) % PV increased by 4.40 (-10.9 - 16.4), 12.70 (-4.3 - 34.8) and 5.10 (-10.7 - 28.5) % 
during S1, S2 and S3, respectively.  Table 2 presents the race – induced perturbations in total and 
differential leukocyte counts. These show increases above the upper limit of the clinical 
reference range16 in the post stage total leukocyte and neutrophil concentrations only.  
 
Table 2. Median (range) total leukocyte and differential white cell concentrations# for the 

















3.92 - 9.88 2,.00 - 7.50 1.00 - 4.00 0.00 - 0.45 0.00 - 0.20 
S1pre 
5.69 
(4.32 - 7.72) 
2.91 
(1.1 - 4.3) 
1.93 
(1.38 - 3.32) 
0.21 
(.06 - 0.65) 
0.035 
(0.02 - 0.08) 
S1post 
12.94* 
(7.90 - 16.00) 
10.87* 
(6.1 - 14.6) 
1.50 
(0.51 - 2.20) 
0.06* 
(0.01 - 0.26) 
0.049 
(0.02 - 0.10) 
S2pre 7.12 (4.53 - 10.10) 
3.60 
(1.7 - 6.0) 
2.06 
(1.43 - 3.70) 
0.24 
(0.06 - 0.72) 
0.050 
(0.01 - 0.08 
S2post 
12.56** 
(8.22 - 19.68) 
10.07** 
(5.7 - 15.2) 
1.77 
(1.11 - 2.92) 
0.05** 
(0.00 - 0.38) 
0.049 
(0.02 - 0.25) 
S3pre 7.63 (6.09 - 10.86) 
4.37 
(1.8 - 5.6) 
2.49 
(1.91 - 4.42) 
0.29 
(0.1 - 0.73) 
0.056 
(0.03 - 0.08) 
S3post 11.05*** (6.79 - 17.87) 
7.55*** 
(5.1 - 14.5) 
1.64 
(1.38 - 2.83) 
0.07*** 
(0.01 - 0.37) 
0.043 
(0.02 - 0.07) 
24PR 7.79 (4.61 - 10.18) 
4.33 
(2.3 - 5.4) 
2.47 
(1.46 - 4.24) 
0.20 
(0.07 - 0.63) 
0.049 
(0.00 - 0.08) 
72PR 7.53 (3.91 - 10.13) 
4.85 
(1.7 - 6.5) 
1.68 
(0.72 - 3.49) 
0.14 
(0.02 - 0.39) 
0.033 
(0.02 - 0.06) 
#Adjusted for plasma volume changes* p<0.05 vs. S1pre, ** p<0.05 vs. S2 pre *** p<0.05 vs. S3 pre 




Phadiatop® test results, peak serum IgE concentrations and URS status of the individual subjects 
are presented in Table 3. Specific IgE antibody concentrations were above > 0.35 IU/ml in seven 
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subjects who were classified as Phadiatop positive,17 while the remaining seven subjects did not 
respond to exposure to the inhalant allergens included in this test.14 In 86% of subjects the peak 
IgE concentrations were recorded at the 24PR time point. Race-induced median (range) serum 
IgE concentrations of the subjects are presented in Figure 2. The overall rise over the three-day 
event, was not significant (p=0.37). Only four URS positive subjects presented with clinically 
elevated IgE concentrations.17 
 
 
Table 3: Individual baseline pre-race Phadiatop® responses and peak serum IgE 
concentrations and URS status (n=14) 
 







1 75.8 227.1 Positive 
2 7.55 54.4 Positive 
3 0.41 56.3 Positive 
4 0.13 23.6 Positive 
5 0.17 19.5 Positive 
6 7.19 445.7 Positive 
7 0.28 46.2 Positive 
8 41.3 274 Positive 
9 0.14 140.8 Positive 
10 0.11 66.8 Positive 
11 0.12 11.3 Positive 
12 8.51 85.6 Negative 
13 0.50 76.1 Negative 
14 0.12 55.4 Negative 





Figure 2.  Median (range) of absolute serum IgE concentrations (IU/ml) of subjects at 8 time points during and after 
the three day, 95km trail running event. *reference range17 
 
Eleven (78.6%) of the subjects presented with URS symptoms post-race (Table 3). The median 
(range) of total symptom scores in these symptomatic subjects is shown in Figure 3. 
 
 
Figure 3. Median (range) upper respiratory symptom scores of the 11 URS positive subjects for the two week period 




Individual pre- and post-race salivary IgA secretion rates (μg IgA x ml-1) are presented in Table 
4 along with the percentage deviation from baseline. Seven of the 14 subjects developed a 
greater than -40% suppression of salivary IgA secretion rate compared to baseline at some point 
post-race, and in two of these subjects the suppression was present at all three post-race testing 
periods. Of the seven cases of IgA suppression five were within the URS positive group. 
 
Table 4: Individual salivary IgA secretion rates (μg sIgA x min-1) at four stages before and 
after the race, as well as percentage deviations from baseline. 
 
Case 







1 268.31 59.59 - 77.79* 98.90 - 63.14* 102.10 - 61.95* 
2 244.13 74.57 - 69.46* 62.06 -74.58* 65.66 - 73.10* 
3 55.62 78.26 40.72 161.98 191.25 137.74 147.66 
4 127.71 81.22 - 36.40 92.01 - 27.95 92.97 - 27.20 
5 75.97 82.48 8.56 59.89 - 21.17 67.82 - 10.74 
6 51.81 63.96 23.45 34.84 - 32.75 33.66  35.04 
7 45.46 179.44 294.70 85.97 89.09 136.39 200.00 
8 185.43 92.38 - 50.18* 140.52 - 24.22 256.81 38.50 
9 199.39 95.21 - 52.25* 171.46 - 14.00 158.19 - 20.66 
10 112.60 79.39 - 29.49 76.26 - 32.27 65.96 - 41.42* 
11 84.16 130.85 55.48 112.43 33.60 134.07 59.31 
12 133.88 113.48 - 15.24 121.78 - 9.04 86.94 - 35.07 
13 55.51 67.65 21.87 80.49 44.99 31.67 - 42.94* 
14 256.96 129.67 - 49.54* 223.30 - 13.10 173.41 - 32.51 
*sIgA value lower than -40% of their mean healthy sIgA concentration indicated a one in two 
chance of contracting an URTI within 3 weeks.18 
 
 
A detailed summary of the general immunological profile and differential diagnosis of the URS 




Table 5. Immunological profile of individual subjects presenting with URS before, during or after the event. 
* C = Cough; RN = Runny Nose; S sneezing; BN = Blocked nose; ST = Sore Throat; HA = Headache; F = Fever; W = Wheeze. Numbers represent the Upper Respiratory Tract Symptom Score and represent the severity of the symptom. 






















































































1 42 80 10:27 M ST (2),  C (7),  
RN (7) 












↑S1 Post (11.2) 
↑S2 Post (12.1) 






-35% -77.8%(S3Post),      
-63.1%(24PR) &     
-61.9% (72PR) 
Reactivation of prior viral 
infection (lymphocytopaenia 
& sIgA) + Allergic Response 
(Phadiatop, IgE) 
2 42 60 13;52 M - - C (2), RN (3), S (3), 
BN (2), ST 
(2), W (3) 
+ No 
(41 – 54) 
NAD 
(0.07 – 0.4) 
NAD 
(0.04- 0.08) 
↑S1 Post (11.0) 





+ 8% -69.5%(S3Post),  
-74.6%(24PR) &     
-73.1% (72PR) 
Infection (sIgA) 







↑S1 Post (10.3) 





-23% - Inflammatory response 
(CRP)# 











-46% - Possible NAR (mild 
response). 
5 33 12.5 12:07 F BN (1), HA (2) 








↑S1 Post (11.4) 
↑S2 Post (10.4) 
10.2 
(S3Post) 
134 ↓ (0.9) at S1 post 
(0.9-2.32) 
-16% - Inflammatory response 
(CRP)# 
 








(13), ST (2), 
HA (4), F 








↑ at S2pots 
(0.25) 
↓ at 24PR 
(0.00) 
↑S1 Post (9.2) 
↑S2 Post (8.4) 
5.5 
(S3Post) 
-88 ↑ S1pre (4.42) & 
24PR (4.24) 
-17% - Infection (sIgA, 
Lymphocytosis) and allergic 
reaction (Phadiatop, IgE, 
eosinophilia, basophilia) 








↑S1 Post (12.4) 
↑S2 Post (15.2) 
↑S3 Post (14.5) 
14.9 
(S3Post) 
454 Borderline ↑ 
(3.94) S3pre 
(1.48-3.94) 
-34% - Inflammatory 
response(CRP)# 
 
8 34 40 14:30 M - ST (2) RN (1) 
RN (2), S 
(2), BN (4), 
















↑S1 Post (10.1) 
↑S2 Post (11.0) 
↑S3 Post (9.8) 
116.3 
(72PR) 
422 ↓(0.72) at 72PR 
(0.72-1.96) 
-63% -50% (S3Post), Infection (lymphocytopaenia 
and sIgA) and allergic 
reaction (Phadiatop, IgE, 
eosinophilia) 
9 47 80 12:16 F C (2), RN (1), S (1), 
BN (1), 
ST (4), 
HA (2), F 
(2) 
- RN (6), S 
(3), BN (4), 
ST (4), HA 









↑S1 Post (10.9) 
↑S2 Post (11.7) 





-35% -52.25% (S3Post), Reactivation of prior viral 
infection (sIgA, 
lymphocytopaenia) Poss. 
allergic component (↑IgE) 
10 42 55 12:22 F S (1), BN (1) 
S (2) RN (3), S 












-13% -41.4% (72PR) Reactivation of prior viral 
infection   












↑S1 Post (10.8) 
↑S2 Post (9.7) 










Table 6. Immunological profile of individual subjects not presenting with URS before, during or after the event. 
 
* C = Cough; RN = Runny Nose; S = Sneezing; BN = Blocked nose; ST = Sore Throat; HA = Headache; F = Fever; W = Wheeze. Numbers represent the Upper Respiratory Tract Symptom Score and represent the severity of the symptom. 























































































S1 Post (11.2) 





+44% - Negative:  
Trivial-- lasting <1 day -
pre-race anxiety? 









↑S1 Post (9.9) 
↑S2 Post (8.7) 





-5% -42% (72PR) Negative: HA not specific 
to URTI; S=trivial 






↑S1 Post (14.6) 
↑S2 Post (11.1) 









Negative : Single 




Of the URS positive group, six of the subjects presented with markers of the presence of 
infection, displaying either disturbances in absolute lymphocyte concentrations or suppression of 
sIgA concentrations.18 Of these six subjects, four also presented with elevated serum IgE 
concentrations with concomitant post-race eosinophilia present in two and basophilia in one.  
 
Isolated elevated serum CRP concentrations above 5 mg/L, were present in four subjects. One 





The incidence of URS in this study (78.6 %) is greater than that reported in most other studies 
investigating URS in runners.5 This is possibly due to the nature of this long distance endurance 
race over three days during which athletes slept in a communal tented village, in addition to 
being exposed to a relatively large range of ambient temperature during the race and a forested 
conservancy area containing a large variety of plant allergens. Another factor to which the higher 
incidence of URS could be attributed was the inclusion of subjects with a prior history of allergic 
hypersensitivity and exclusion of subjects who reported intake of anti-histamines. 
 
In the evaluation of the findings of the 11 URS positive cases a number of factors were taken 




In interpreting the lymphocyte concentrations in this study, a prolongation of the exercise-
induced reduction of lymphocyte counts5 which persisted for 72 hours following completion of 
the race, was regarded as clinically significant. Furthermore, depression or elevation of absolute 
lymphocyte count out of clinical range17 at any stage of the race was taken as indication of 




It is well accepted that prolonged high intensity exercise is associated with decreases in both 
sIgA concentrations and secretion rates5 and there is evidence to suggest that low levels of 
salivary sIgA or substantial transient falls in sIgA are associated with increased risk of URTI.5,18 
We used the criterion of a drop in sIgA secretion rate of more than 40% which Neville et al.18 
associated with a 50% risk of developing a subsequent URTI, in conjunction with a clinically 
significant suppression or elevation of lymphocyte count, as indicative of possible infectious 
causes of URS. 
 
Six (54%) of the post-race URS positive subjects presented with findings suggestive of the 
presence of infectious URS which is higher than previously reported by Spence et al.6 and  Cox 
et al.7  Of these six, three subjects displayed a pattern of URS during the two weeks prior to the 
race which is suggestive of reactivation of a viral infection. This reactivation in 21.4% of the 
total of 14 subjects strongly supports the findings of Reid et al.8 who documented reactivation of 
the Epstein Barr virus in 19.5% of subjects. 
 
Allergy? 
The incidence of allergic diseases, which can closely mimic URTI symptoms19 is increasing13,20-
22 with the cited rates of allergic rhinitis in athletes currently being higher than in the normal 
population.22 The Phadiatop® assay which measures specific serum IgE concentration in 
response to 23 possible inhaled allergens,14 was positive in 50 % of the sample and confirms 
previous findings of Schwellnus et al. of the large percentage incidence of pre-race allergic 
hypersensitivity.23  
 
Furthermore, participants using anti-histamines (n=2) were excluded from the study due to the 
effect of this medication on URS21 in order to increase the validity of our differential diagnoses. 
Of interest is the low dependence on anti-histamines in our group (n=22) confirming the findings 
of Randolf et al.24 in which only 0.5% were using anti-histamine medication.  
 
Although the eosinophilia which is typical of atopic asthma and allergic rhinitis,25,26 is 
characteristically most detectable in local tissue and mucosal secretions, mild serum eosinophilia 
is also commonly induced by allergic reactions.26 In this study two of the subjects developed 
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clinically significant eosinophilia. Both of these subjects presented with simultaneous elevations 
in serum IgE, in addition to being Phadiatop® positive and symptomatic.  
 
The contribution of basophils to the acute phase allergic response by amplifying the production 
of IgE is well recognised.26 In this study, one subject displayed clinically significant basophilia17 
along with eosinophilia, raised serum IgE concentrations17 and URS, suggestive of an allergic 
hypersensitivity reaction. 
 
While the protective role of serum IgE against reactive airway disease, is well documented in 
susceptible individuals, significantly elevated serum IgE concentrations are also indicative of the 
hypersensitivity reactions occurring during atopic diseases such as allergic rhinitis.26 Therefore 
eosinophilia or basophilia detected in conjunction with elevated circulating IgE concentration 
and self-reported URS was taken to represent the activation of an allergic process in this study. 
 
Of greatest interest was the finding that markers of an isolated allergic response were not present 
in these 14 case studies.  In all four cases that presented with positive markers of an allergic 
reaction, it was associated with markers of de novo infection or possible reactivation of prior 




In this study elevations of serum hs-CRP concentrations above 5mg/L were used to detect the 
presence of an acute phase reaction. As this may however have been due to a broad range of 
acute or chronic inflammatory responses to the presence of infection or muscular inflammation, 
the overall immunological profjile of each individual was considered before making a 
differential diagnosis.  Therefore only in the absence of clinically significant indicators of 
infection, were isolated elevations in CRP concentrations regarded as indicative of an 
inflammatory response.  
 
An isolated systemic acute phase response which may have triggered an inflammatory response 
within the respiratory tract and explain the development of non-infectious sore throats and 
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rhinitis,3,5,10 was evident in four out of the 11 (45.4%) of the sample presenting with URS in the 
absence of systemic markers of concomitant infection or allergic reaction.  
 
Firstly, we confirm previous findings that raised hs-CRP is not linked to allergic responses.27 The 
hs-CRP concentrations did also not increase to beyond the recommended range for the presence 
of mild inflammation28 in these four subjects and further as yet unpublished data from our 
laboratory,29 reflect the absence of evidence of substantial skeletal muscle damage (serum 
creatine kinase concentrations > 2000U/L). It would nevertheless have been advisable to have 
confirmed this diagnosis by examining the sputum for markers of local inflammation in the 
respiratory tract.3 This would be recommended as a consideration for future studies. 
 
Non-allergic rhinitis? (NAR) 
Although NAR mimics allergic rhinitis, it presents with normal serum IgE levels and a negative 
Phadiatop® test for atopy30,31 and the prevalence in the adult population is believed to be at least 
25%.31 The exact cause is unknown, but the underlying inflammatory mechanisms that have 
been postulated in athletes presenting with conditions such as “runners nose,”13 have been related 
to repeated dehydration injury, extreme ambient temperatures, irritant pollutant and allergen 
exposure and cortisol and catecholamine fluctuations.31 In this study, there appeared to be 
evidence of this condition in one of the 14 subjects surveyed in whom the elevation in CRP was 
so slight that NAR could possibly be suggested.  
 
Conclusion  
Taken together, the findings of these 14 case studies indicate the absence of allergic 
responsiveness alone in the aetiology of URS in these trail runners. Evidence of allergic 
responsiveness was present in four subjects, but in each case this was linked to systemic 
indicators of the presence of a concurrent infection, rather than inflammation.   
 
Although the actual cause and effect relationship between allergic responsiveness and a 
concomitant infectious response has not yet been confirmed, the findings of this study appear to 
suggest that anti-histamine or other anti-allergy medication alone will not suffice in the treatment 
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As the analysis conducted in chapter 3 revealed that not all of the athletes with elevated 
serum IgE concentrations were Phadiatop positive, it was decided to conduct a 
retrospective analysis of the validity of Phadiatop status in predicting pre-disposition to 
allergy-associated RTS. As serum IgE concentrations are not affected by the intake of anti-
histamines, subjects using these medications were included in this analysis which was 




This is the first analysis of the validity of Phadiatop testing when applied to trail runners 
participating in a country setting in South Africa. 
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Phadiatop® testing in assessing pre-disposition to Respiratory Tract 











School of Laboratory Medicine and Medical Sciences *  
College of Health Sciences, 
University of KwaZulu-Natal, 
Westville, 
Durban, South Africa 
 
 




Address for Correspondence: 
Prof E M Peters-Futre,  
School of Laboratory Medicine and Medical Sciences, 
College of Health Sciences, 
University of KwaZulu-Natal, 
Westville, 






To validate the use of the Phadiatop® test as a predictor of allergy-associated Respiratory Tract 
Symptoms (RTS) in trail runners. 
 
METHODS:  
The incidence of self- reported RTS was documented in 16 runners for 31 days and related to the 
Phadiatop® status and circulating markers of allergic responses at 8 time points before, during 
and after a three-day 95 km trail run. 
OUTCOME MEASURES: 
Incidence of RTS, pre-race Phadiatop® status, changes in concentrations of serum IgE (sIgE), 
differential leukocyte counts. 
RESULTS:  
Twelve (75%) athletes presented with post-race RTS and seven (58%) of these were Phadiatop® 
positive. In only four (57%) of the symptomatic subjects who had positive Phadiatop® status, 
was the RTS accompanied by peak sIgE concentration > 100 IU/ml. There was no significant 
difference between the eosinophil and basophil concentrations of the positive and negative 
groups (p>0.05). One of the Phadiatop® negative subjects presented with RTS as well as peak 




The Phadiatop® assay does not accurately predict the development of post-exercise RTS of 





Of concern since the early 1980’s has been the high incidence of upper respiratory tract 
infections  in athletes during periods of intensive exercise training and exhaustive endurance 
events.1,2 This has resulted in interrupted training schedules and impaired performance in 
competitive events. For many years exercise immunologists have sought methods of identifying 
the cause of these symptoms which have now been extended to the lower respiratory tract.3  
 
It has been shown that 30%-40% of post exercise Respiratory Tract Symptom (RTS) cases are 
the result of infection, another 30% resulting from inflammatory causes and the final 30% 
resulting from unknown causes.2,4-6 Numerous theories have been proposed in the development 
of non-infective post-exercise RTS, including the development of hyper reactive airways,7  a 
run-away inflammatory response,8 a reactivation of latent viral infection 6 and allergic reaction.3,9 
 
 Athletes have been documented to experience higher rates of allergic diseases than the general 
population10 and that the cited incidence of allergy among Olympic athletes is steadily 
increasing.11  As exercise-induced symptoms of infection of the respiratory tract can closely 
mimic those of an allergic reaction3 and exercise is known to induce a TH2 dominant 
immunological shift2, it may up-regulate an allergic response in those already sensitized,9 and 
increased exposure of athletes to irritants and allergens3,11  may contribute towards this.  
 
Although the skin prick test (SPT), is generally accepted as the standard method for detecting 
IgE related allergic sensitization12 its limitations include lower response in the elderly, difficulty 
in grading the response in darkly pigmented persons, contraindication for the pregnant, the 
quality and selection of allergens and potential risk of anaphylaxis.13  
 
Specific IgE antibody testing is accepted as an alternative to the SPT12 and combination tests 
such as the Phadiatop® assay (Pharmacia & Upjohn Diagnostics, Uppsala, Sweden) 
simultaneously test for IgE to a mixture of allergens causing common inhalant allergies. 
Allergens included in the Phadiatop® assay are Artemisia, dust mites (D. pteronyssinus and D. 
fariane), mixed moulds (Penicillium, Cladosporium, Aspergillus and Alternaria), pet dander (cat 
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and dog), mixed grasses (Parietaria, Lolium, Phleum and Cynodon), and mixed trees (Acer, 
Betula, Olea, Salix, Pinus, Ulmus, Quercus, Eucalyptus, Acaciaand Malaleuca).14 This  assay has 
been found to offer satisfactory accuracy for diagnosing of IgE allergic sensitization in the 
general population with a sensitivity of 70.8% and a specificity of 90.7% compared to the SPT.12  
 
The primary objective of this study was therefore to investigate the validity of the Phadiatop® 
test as a predictor of allergy associated RTS in athletes competing in a 3 day, 95km, trail run. 
The secondary objective was to document the incidence of RTS pre-, during and post-event and 
relate these to the concentrations of serum IgE, leukocyte parameters and Phadiatop® status of 




This longitudinal study was part of a larger study examining physiological responses during the 
Three Cranes (a 95km, three-day trail run) in Karkloof, KwaZulu-Natal on 25-27 February 2011.  
Local institutional ethical approval was obtained and a sample of 22 volunteers signed informed 
consent forms. 
 
After routine baseline testing on the afternoon before the race, venous blood samples were 
collected at a total of eight time-points, before and after each day’s stage (S1pre, S1post, S2pre, 
S2post, S3pre and S3post), 24 hours post race (24PR) and 72 hours post race (72PR). RTS data was 
collected over a 31 day period, from 14 days prior to the race until the 14th day after the race. Of 
the 22 subjects, 16 completed the race and complied with all the study requirements. Two 
subjects were excluded as a result of failure to complete the race and a further four did not 
complete post race testing.  
 
Athletes were asked to record the daily incidence and severity of RTS pre, during and post-race 
using a graded 1-3 point scoring system. Symptoms monitored included cough, runny nose, 
sneezing, blocked nose, sore throat, headache, fever, tight chest and itchy eyes. A total 
respiratory tract symptom index score was determined using the sum of severity scores 




To determine which subjects qualified for post-exercise RTS, any subjects presenting with a 
single RTS lasting < 2 days or any non-specific symptom (e.g. headache, itchy eyes) not 
accompanied by a RTS lasting > 1 day, were excluded. A peak post-stage or race serum IgE 
(sIgE) concentration below the clinically significant range (100IU/ml) excluded the possibility of 
the RTS being of allergic origin. 
 
Full blood counts, pre-race Phadiatop® status and sIgE concentrations were determined by a 
local pathology laboratory (Ampath Laboratories, Howick) using an automated UniCAP system. 
In the Phadiatop® assay, concentrations higher than 0.35 IU/ml represented a positive response 
irrespective of range.14 
 
Exercise-induced changes in plasma volume (PV) over this three day event were determined 
from pre- and post-exercise haematocrit and haemoglobin concentrations.15 Post exercise sIgE 
and concentration dependant leukocyte counts were adjusted for percentage exercise-induced 
change in PV. 
 
After confirmation of the absence of normality of the data, they were logarithmically 
transformed. A Generalized Linear Model was applied to the median (range) sIgE and 
differential leukocyte concentration data from multiple subjects over multiple time points and 
between Phadiatop® positive and negative groups. The Mann-Whitney U test was used to 
compare the RTS data pre- and post-race and between Phadiatop® positive and negative groups. 
Data are presented as the median (interquartile range, IQR) in box and whisker plots in Figures 1 




Of the 16 subjects (12 female, 4 male; 25-50 years), nine were Phadiatop® positive and seven, 
Phadiatop® negative. The median and range of BMI (23.8, 18-7 - 27.7 vs. 20.9, 19.7 - 25.3) and 
% body fat (20.9, 15.7 - 29.3 vs. 23.7, 17.2 - 30.6) did not differ significantly between 
Phadiatop® positive and negative groups. Baseline testing of vital signs were within the normal 
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range and subjects did not present with evidence of any medical condition that could place their 
health at risk. The results of the Phadiatop® assay and peak sIgE concentrations are presented in 
Table 1. 
 






























1 8.51 85.64 ( 24PR) 5 0.13 23.64(24PR) 
2 75.80 227.14(24PR) 6 0.17 19.46(72PR) 
3 7.55 54.38(24PR) 10 0.12 55.44(24PR) 
4 0.41 56.32(24PR) 12 0.28 33.58(24PR) 
7 7.19 445.74(24PR) 14 0.12 11.30(24PR) 
8 3.42 240.48(72PR) 15 0.14 140.82(24PR) 
9 0.50 76.13(24PR) 16 0.11 66.79(24PR) 
11 9.49 63.14(24PR)    
13 41.30 274.0(S1pre)    
Median 7.55# 85.64# Median 0.13 33.58 
      * SIgE Reference range: Phadiatop® 0.00-0.35IU/ml 
** Reference range: Total SIgE 0.00-100 IU/ml 
# p < 0.001 vs. Phadiatop®  negative group, Generalised Linear Model 
 
 
Twelve subjects (75%) met the criteria for post race RTS. Of these, seven (58%) were 
Phadiatop® positive and five (42%) were Phadiatop® negative. The median (IQR) pre-and post-






Figure 1. Median (IQR) pre-race (left) and post-race (right) total RTS index scores of Phadiatop® positive* (n=9) 
and negative (n=7) groups. 




The median (IQR) sIgE concentrations of the subjects (adjusted for PV) are presented in Figure 
2. There was a non-significant (p=0.37) rise in the sIgE concentrations of the entire group over 
the course of testing, with highest concentrations being recorded in 75% of subjects at the 24PR 
time period. There was a highly significant (p<0.001) difference between the sIgE concentrations 




Figure 2. Median (IQR) of absolute sIgE† concentrations* of Phadiatop® positive and negative groups, at 8 stages 
during and after a 3 day, 95km trail run.  
†reference range: 0-100IU/ml 
*adjusted for plasma volume 
 
Concentrations of sIgE reached clinical significance (peak sIgE concentration > 100 IU/ml) in 
five (42%) of the 12 RTS positive subjects (four Phadiatop® and RTS positive subjects and one 
Phadiatop®  negative and RTS positive subject). 
 
There was no significant exercise-induced elevation in PV adjusted concentrations of either 
basophils or eosinophils over time ( p>0.05) and the difference between Phadiatop® positive and 
negative groups in terms of eosinophil or basophil response to three days of exercise was not 







The incidence of post exercise RTS in this study (n=12, 75%) was higher than most other studies 
investigating runners have reported.1-3 This was possibly due to inclusion of subjects with prior 
history of allergy, as in most previous studies allergy was seen as a confounding factor for the 
determination of URTI incidence and excluded.  
 
Interestingly, in this field trial subjects with systemic evidence of RTS associated with an 
allergic reaction accounted for 42% (n=5) of the 12 cases with post-exercise RTS. However  as 
seen by the lack of significance between post race RTS incidence in Phadiatop®  positive and 
negative groups ( Fig 1), the incidence of post race RTS symptoms was not defined by the 
Phadiatop® test.  
 
The primary finding of this study was however that of the seven Phadiatop®  positive subjects 
who developed post-race RTS, only four (58%) displayed clinically elevated sIgE concentrations 
above the cut off point for allergy (sIgE > 100IU/ml). In addition, the mildly elevated eosinophil 
concentrations often seen in allergic responses13 were not evident in the Phadiatop positive group 
(P>0.05). 
 
Although specific sIgE antibody testing (or SPT) provides evidence of sensitization to an 
allergen, an allergic disease response only develops once the individual is exposed to that 
particular allergen. Therefore although the Phadiatop® test may provide satisfactory accuracy in 
identifying predisposition to allergic responsiveness to airborne allergens, on its own, it may not 
predict the development of allergic disease in trail runners. Due to the fixed selection of allergens 
it is theoretically possible to miss subjects who are sensitized to less common inhalant allergens 
(such as local flora or fauna), as was the case in one of our subjects. 
 
The predictive validity of the Phadiatop® assay for the incidence of race-induced RTS of allergic 
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CHAPTER 5 – CONCLUSIONS 
 
The present study was designed to examine the role that allergic predisposition or reaction plays 
in the development of post exercise RTS.  Having examined the results of the studies it is now 
possible to return to the hypotheses stated at the beginning of the study. 
1) Firstly, this work supported the hypothesized increase in RTS within the post race period.  
Both analyses showed an incidence of post-exercise RTS equal to or greater than 75 %, 
which is higher than previous studies involving runners.  This is possibly due to the 
inclusion of allergic subjects within the test group. 
 
2) Secondly, it was also hypothesized that the effect of the three-day trail run on systemic 
markers of immune system activation would be cumulative.  The race did result in a 
cumulative effect on hs-CRP concentrations and an exercise effect was noted in total 
leukocyte, neutrophil and lymphocyte concentrations (as is to be expected after 
exhaustive exercise), resulting in lasting perturbations.  The effect on other differential 
cell count parameters however, was not significant and concentrations had returned to 
pre-race concentrations within 72 hours of the final stage.  The three-day race did not 
have a strictly cumulative effect on sIgA concentrations, with only seven subjects 
showing suppression and only two of those being cumulative.  No cumulative effect was 
noted for markers of allergy, although mean exercise-induced sIgE concentrations rose 
throughout the testing period, the effect was not statistically significant (unlike the 
findings of Aldred et al. 2010) and no cumulative effect was noted in eosinophil or 
basophil concentrations. 
 
3)  Thirdly, the fact that the incidence of RTS was not related to any single systemic or 
salivary marker of immune function was confirmed.  As a series of 14 case studies was 
undertaken of the general immune profile and RTS status of trail- running subjects, it is 
possible to confidently support the above hypothesis.  Subjects who were positive for 
post race RTS, presented with a variety of disturbances in immune parameters with no 
one marker displaying a dominant or significant relationship.  Athletes with RTS 
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presented with a variety of allergic, infectious and inflammatory markers reflecting a 
more multi-faceted aetiology to their symptoms. 
 
4) Fourthly, it was found that Phadiatop® positive subjects (n=9) did not present with raised 
markers of allergic activation, as only 44% (n=4) had clinically elevated sIgE 
concentrations at any point during the event. 
 
5) Finally, it was demonstrated that the Phadiatop® Assay does not accurately predict the 
development of post exercise RTS in trail-runners. 
 
Although this study did not demonstrate an exclusive connection between allergy (either reaction 
or predisposition towards) alone and the development of post exercise RTS, it did show that a 
large percentage of symptomatic subjects display signs of allergic reaction (36/42%).  Taken 
together, these results suggest that, whilst new infections, reactivation of previous infections and 
inflammation all appear to contribute to the development of post exercise respiratory symptoms, 
allergy cannot be discounted as a contributory factor.  Based on this it is recommended that 
runners presenting to their physician with post exercise RTS, or a history of recurring RTS, be 
examined comprehensively for infection, chronic viruses, other systemic inflammatory disease 
and allergic reaction. 
One of the most significant findings to emerge from this study is that allergic reaction, or 
clinically elevated sIgE concentrations were only evident in subjects with concomitant immune 
perturbations associated with increased risk of infection.  This raises the question whether having 
clinically elevated sIgE concentrations increases susceptibility to infectious post exercise RTS?  
This potential link between allergic reaction and infectious RTS requires further study. 
Another major finding was that the Phadiatop® assay cannot be used to screen for an increased 
susceptibility toward RTS.  It is also concerning that this assay cannot be adjusted to account for 
local flora and fauna and that it does not cover food allergens.  Therefore it is recommended that 
skin prick testing for a battery of routine allergens be used to diagnose atopic predisposition and 
total sIgE concentrations be used to assess tendency toward allergic reaction.  Furthermore, 
recreational athletes appear to take little allergy medication (9% antihistamines in this study and 
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0.5% anti-histamine usage by recreational runners before a race observed by Randolph et al., 
(2006)).  It would therefore be interesting to determine whether medications that lower sIgE 
concentrations or block allergic reactions may reduce the incidence of infectious RTS. 
The findings in this study are subject to a number of limitations.  Firstly, the project used a 
convenience sample that may not have been equally representative of gender and racial 
demographics.  Secondly, the scope of this Masters (by course-work) project and concomitant 
financial considerations necessitated a limitation of the number of immunological tests that were 
performed.  Thirdly, infection or lack thereof was not confirmed through physician examination, 
culture of swabs or x-ray, blood test results and self reported data were relied upon.  Lastly, the 
extensive level of commitment required from each subject, who was requested to fully comply 
with all requirements of this work over a 31-day period, limited the number of athletes who were 
prepared to make themselves available to participate in the study as well as the number of 
athletes who were able to fully comply.  
It is therefore recommended that future studies in this area carefully explore strategies of 
increasing the number of subjects.  Additionally a detailed physical examination of subjects 
presenting with post-race RTS, with the aim of detecting and identifying pathogens, is 
recommended.  This would aid in differentiating between allergic reaction and infectious RTS 
and help to define the relationship between these two factors. Furthermore, exploration of 
adaptations to the current Phadiatop® assay which would increase its predictive validity for trail 
runners in South Africa is another important future research consideration.  
Despite its limitations, this Masters (by course-work) project has produced two preliminary 
novel findings that have gone some way towards developing the understanding of the aetiology 
of allergic respiratory symptoms in trail runners and the direction of future research in this area. 
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Physiological assessment of participants in a three-day trail run event:  markers of muscle   damage,   
hydration and immune status. 
 
 
                                                         SUBJECT CONSENT FORM 
 
I, ………………………………………….. hereby agree to participate in a research study to be performed by 
Dr. Rentia Denissen, Dr Anton de Waard, Mr. Navin Runjit Singh and Professor Edith Peters-Futre in the 
Department of Human Physiology in the College of Health Sciences of the University of KwaZulu-Natal. I 
have been informed about the study by the principal investigator, Professor Peters-Futre.  
 
I understand that the basic procedures to be carried out are to include:  
1. Completion of URTI questionnaire for 14 days prior to the race  
Assessment of height, mass and percentage body fat, heart rate, blood pressure and peak flow prior to 
registration on 24 February 
2. Completing two questionnaires as well as providing a small vial of blood (2ml) to perform an allergy test 
at the pre-race briefing 
2. Completion of a brief questionnaire, giving a urine and saliva sample and the taking of three vials of blood 
(a total of no more than 14ml of blood), twice daily (before and after each stage of the three-day event) 
3. Completion of a post-stage questionnaire, giving a urine sample and three vials of blood 24, 48 and 72 hrs 
after the race finishes 
4. Accurately measuring all fluid consumed and urine voided throughout the duration of the race, and 
recording the incidence of upper respiratory tract infection symptoms during the 2-week post-race period 
5. Completion of a URTI questionnaire for 14 days following the race 
 
The details of these procedures have been explained to me in full. I am aware that a certain level of 
discomfort may occur when the blood is taken and that this procedure may be accompanied by certain 
medical risks including infection and inflammation of the vein.    
 
I understand that the study forms part of the Masters degrees of Drs Rentia Denissen and Anton de Waard 
and that the results may be published.  
 
I understand that participation is entirely voluntary and that I may withdraw from the study at any time. 
 
I may contact the principal investigator of the project, Professor Peters Futre at 073- 7597974 at any time if I 
have questions about the research or if I are injured as a result of the research. 
 
_________________                        ______________ 
Signature of Participant                                Date 
 
____________________                  __________________ 







PRE RACE SELF REPORTED 
URTI SYMPTOMS 
Severity Rating:  0 = Nothing;     1 = Mild 













11 Feb                   
12 Feb                   
13 Feb                   
14 Feb                   
15 Feb                   
16 Feb                   
17 Feb                   
18 Feb                   
19 Feb                   
20 Feb                   
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22 Feb                   
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POST RACE SELF REPORTED 
URTI SYMPTOMS 
Severity Rating:  0 = Nothing;     1 = Mild 










Headache Fever Wheeze/ 
tight chest 
Watery / Itchy 
Eyes 
25 Feb                   
26 Feb                   
27 Feb                   
28 Feb                   
1 March                   
2 March                   
3 March                   
4 March                   
5 March                   
6 March                   
7 March                   
8 March                   
9 March                   
10 March                   
11 March                   
12 March                   
13 March                   
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